Fisher Asset Management LLC Decreases Holdings in DexCom, Inc. $DXCM

Fisher Asset Management LLC lowered its position in DexCom, Inc. (NASDAQ:DXCM) by 28.3% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 286,620 shares of the medical device company’s stock after selling 113,251 shares during the quarter. Fisher Asset Management LLC owned approximately 0.07% of DexCom worth $25,019,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also bought and sold shares of the business. Nuveen LLC bought a new stake in shares of DexCom in the 1st quarter worth approximately $554,893,000. Norges Bank purchased a new position in DexCom in the 2nd quarter worth $453,279,000. Groupama Asset Managment lifted its stake in DexCom by 79,043.1% in the second quarter. Groupama Asset Managment now owns 4,016,513 shares of the medical device company’s stock worth $350,601,000 after purchasing an additional 4,011,438 shares during the last quarter. Massachusetts Financial Services Co. MA boosted its position in DexCom by 106.8% during the second quarter. Massachusetts Financial Services Co. MA now owns 6,605,687 shares of the medical device company’s stock valued at $576,610,000 after buying an additional 3,410,858 shares during the period. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in shares of DexCom by 22.6% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 10,123,525 shares of the medical device company’s stock valued at $691,336,000 after buying an additional 1,868,241 shares during the last quarter. 97.75% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of research firms have recently weighed in on DXCM. Stifel Nicolaus began coverage on DexCom in a research note on Tuesday, October 21st. They issued a “buy” rating and a $85.00 target price for the company. Evercore ISI initiated coverage on DexCom in a research note on Tuesday, November 25th. They issued an “in-line” rating and a $68.00 price target on the stock. Argus dropped their price objective on DexCom from $100.00 to $90.00 and set a “buy” rating for the company in a research note on Friday, November 7th. Royal Bank Of Canada cut their target price on shares of DexCom from $100.00 to $85.00 and set an “outperform” rating on the stock in a report on Friday, October 31st. Finally, Cowen reiterated a “buy” rating on shares of DexCom in a report on Friday, October 24th. Three analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, DexCom has a consensus rating of “Moderate Buy” and a consensus target price of $87.27.

DexCom Stock Performance

Shares of DXCM stock opened at $64.45 on Wednesday. The company has a quick ratio of 1.38, a current ratio of 1.56 and a debt-to-equity ratio of 0.45. The stock has a fifty day moving average of $64.12 and a 200 day moving average of $75.45. The firm has a market capitalization of $25.14 billion, a price-to-earnings ratio of 35.81, a PEG ratio of 1.36 and a beta of 1.51. DexCom, Inc. has a 52 week low of $54.11 and a 52 week high of $93.25.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings data on Thursday, October 30th. The medical device company reported $0.61 EPS for the quarter, topping the consensus estimate of $0.57 by $0.04. The business had revenue of $1.21 billion during the quarter, compared to analyst estimates of $1.18 billion. DexCom had a net margin of 15.96% and a return on equity of 30.65%. The company’s revenue for the quarter was up 21.6% on a year-over-year basis. During the same period in the prior year, the business earned $0.45 EPS. As a group, research analysts expect that DexCom, Inc. will post 2.03 earnings per share for the current year.

Insiders Place Their Bets

In other news, EVP Sadie Stern sold 1,466 shares of the stock in a transaction that occurred on Thursday, September 4th. The stock was sold at an average price of $80.00, for a total value of $117,280.00. Following the completion of the transaction, the executive vice president owned 105,223 shares of the company’s stock, valued at approximately $8,417,840. This represents a 1.37% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Kyle Malady sold 667 shares of the firm’s stock in a transaction that occurred on Friday, September 5th. The shares were sold at an average price of $80.86, for a total value of $53,933.62. Following the completion of the transaction, the director owned 22,667 shares of the company’s stock, valued at approximately $1,832,853.62. The trade was a 2.86% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 9,999 shares of company stock valued at $619,391 over the last ninety days. 0.32% of the stock is owned by corporate insiders.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.